Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLSI Greenwich LifeSciences	$8.76 -1.6%	$9.58	$8.06 ▼ $18.15	$118.98M	1.69	46,332 shs	91,197 shs
GTHX G1 Therapeutics	$7.15	$7.13	$1.08 ▼ $7.19	$373.81M	1.66	1.70 million shs	N/A
MREO Mereo BioPharma Group	$2.74 -3.9%	$2.47	$1.58 ▼ $5.02	$453.15M	0.48	1.09 million shs	1.40 million shs
TRVI Trevi Therapeutics	$5.75 -3.5%	$6.36	$2.36 ▼ $7.48	$699.07M	0.59	1.38 million shs	1.21 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLSI Greenwich LifeSciences	-1.57%	-4.78%	-10.70%	-17.75%	-46.16%
GTHX G1 Therapeutics	0.00%	0.00%	0.00%	0.00%	+188.31%
MREO Mereo BioPharma Group	-3.86%	-0.72%	+22.32%	+16.60%	-31.16%
TRVI Trevi Therapeutics	-3.52%	-9.31%	-8.59%	-13.01%	+112.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	Company Ownership	Earnings & Valuation
GLSI Greenwich LifeSciences	1.5281 of 5 stars	3.5	1.0	0.0	3.3	0.0
GTHX G1 Therapeutics	0.4493 of 5 stars	1.0	0.0	3.8	0.0	0.6
MREO Mereo BioPharma Group	1.2322 of 5 stars	3.6	1.0	0.0	1.7	0.0
TRVI Trevi Therapeutics	1.7028 of 5 stars	3.7	2.0	0.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLSI Greenwich LifeSciences	3.00	Buy	$39.00	345.21% Upside
GTHX G1 Therapeutics	2.00	Hold	$4.50	-37.06% Downside
MREO Mereo BioPharma Group	3.20	Buy	$7.60	177.37% Upside
TRVI Trevi Therapeutics	3.33	Buy	$20.29	252.80% Upside

Current Analyst Ratings Breakdown

Latest GTHX, MREO, GLSI, and TRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/2/2025	TRVI Trevi Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00
5/28/2025	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$21.00
5/20/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
5/13/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
4/21/2025	GLSI Greenwich LifeSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $39.00
4/9/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
4/8/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
3/27/2025	MREO Mereo BioPharma Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00
3/26/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.19 per share	N/A
GTHX G1 Therapeutics	$58.20M	6.42	N/A	N/A	$0.68 per share	10.51
MREO Mereo BioPharma Group	$10M	43.57	N/A	N/A	$0.39 per share	7.03
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.30 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLSI Greenwich LifeSciences	-$15.79M	-$1.26	N/A	N/A	N/A	N/A	-450.87%	-333.18%	8/12/2025 (Estimated)
GTHX G1 Therapeutics	-$47.97M	-$0.62	N/A	N/A	N/A	-76.93%	-136.98%	-39.33%	N/A
MREO Mereo BioPharma Group	-$43.25M	-$0.07	N/A	N/A	N/A	N/A	-69.33%	-57.27%	8/12/2025 (Estimated)
TRVI Trevi Therapeutics	-$47.91M	-$0.45	N/A	N/A	N/A	N/A	-58.41%	-52.52%	8/6/2025 (Estimated)

Latest GTHX, MREO, GLSI, and TRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2025	Q1 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/13/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$72.50 million	N/A
5/6/2025	Q1 2025	TRVI Trevi Therapeutics	-$0.13	-$0.09	+$0.04	-$0.09	N/A	N/A
4/15/2025	Q4 2024	GLSI Greenwich LifeSciences	-$0.21	-$0.61	-$0.40	-$0.61	N/A	N/A
3/26/2025	Q4 2024	MREO Mereo BioPharma Group	$0.02	-$0.01	-$0.03	-$0.01	$72.50 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
GTHX G1 Therapeutics	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLSI Greenwich LifeSciences	N/A	1.91	1.91
GTHX G1 Therapeutics	1.34	2.48	2.12
MREO Mereo BioPharma Group	N/A	8.92	8.92
TRVI Trevi Therapeutics	N/A	15.38	15.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLSI Greenwich LifeSciences	4.16%
GTHX G1 Therapeutics	24.21%
MREO Mereo BioPharma Group	62.83%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
GLSI Greenwich LifeSciences	51.67%
GTHX G1 Therapeutics	6.11%
MREO Mereo BioPharma Group	5.50%
TRVI Trevi Therapeutics	18.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLSI Greenwich LifeSciences	3	13.37 million	6.46 million	Not Optionable
GTHX G1 Therapeutics	170	52.28 million	49.09 million	Optionable
MREO Mereo BioPharma Group	40	159.00 million	150.26 million	Optionable
TRVI Trevi Therapeutics	20	117.29 million	95.83 million	Optionable

GTHX, MREO, GLSI, and TRVI Headlines

Recent News About These Companies

Trevi Therapeutics Stockholders Approve Key Amendments

June 17, 2025 | tipranks.com

Q2 EPS Estimate for Trevi Therapeutics Lifted by Analyst

June 15, 2025 | americanbankingnews.com

Leerink Partnrs Has Bullish Forecast for TRVI Q2 Earnings

June 13, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Trading Down 4.8% - Time to Sell?

June 9, 2025 | marketbeat.com

Two Sigma Investments LP Purchases New Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

June 9, 2025 | marketbeat.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLC

June 7, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street Zen

June 7, 2025 | marketbeat.com

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

June 5, 2025 | prnewswire.com

Ameriprise Financial Inc. Acquires 63,067 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

June 5, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up - Time to Buy?

June 4, 2025 | marketbeat.com

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

June 3, 2025 | prnewswire.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 7.1% - Here's Why

June 3, 2025 | marketbeat.com

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

June 2, 2025 | prnewswire.com

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

June 2, 2025 | benzinga.com

Trevi Therapeutics (NASDAQ:TRVI) Reaches New 12-Month High - What's Next?

June 2, 2025 | marketbeat.com

Trevi Therapeutics' (TRVI) "Buy" Rating Reiterated at D. Boral Capital

June 2, 2025 | marketbeat.com

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 2, 2025 | prnewswire.com

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 1, 2025 | prnewswire.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts

June 1, 2025 | marketbeat.com

Research Analysts Issue Forecasts for TRVI Q2 Earnings

May 31, 2025 | marketbeat.com

H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating

May 29, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTHX, MREO, GLSI, and TRVI Company Descriptions

Greenwich LifeSciences NASDAQ:GLSI

$8.76 -0.14 (-1.57%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$9.17 +0.41 (+4.68%)

As of 06/23/2025 07:01 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

G1 Therapeutics NASDAQ:GTHX

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Mereo BioPharma Group NASDAQ:MREO

$2.74 -0.11 (-3.86%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$2.77 +0.03 (+1.13%)

As of 07:00 AM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Trevi Therapeutics NASDAQ:TRVI

$5.75 -0.21 (-3.52%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$5.91 +0.16 (+2.85%)

As of 07:00 AM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time